Alnylam Pharma (ALNY) Tops Q4 EPS by 46c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $283.82 +2.06%
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +409.4%
Financial Fact:
Net revenues from research collaborators: 8.71M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q4 EPS of ($1.39), $0.46 better than the analyst estimate of ($1.85). Revenue for the quarter came in at $335.04 million versus the consensus estimate of $312.2 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Ennis (EBF) Reports In-Line Q1 EPS
- Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
